169
Participants
Start Date
July 31, 2024
Primary Completion Date
December 30, 2026
Study Completion Date
December 30, 2027
FPI-2053
FPI-2053 is a bispecific antibody that targets EGFR and cMET
[111In]-FPI-2107
"\[111In\]-FPI-2107 is an imaging agent in which indium-111 is conjugated to FPI-2053.~Participants will have a fixed dose of \[111In\]-FPI-2107 followed by imaging scans (with or without pre-administration of FPI-2053)."
[225Ac]-FPI-2068
"\[225Ac\]-FPI-2068 is a radiopharmaceutical therapy in which an alpha emitter, actinium-225, is conjugated to FPI-2053.~Participants will be dosed through IV administration every 56 days for up to 3 cycles of the Treatment Period."
WITHDRAWN
UPMC Hillman Cancer Center Research Pavilion, Pittsburgh
RECRUITING
Cleveland Clinic, Cleveland
RECRUITING
University of Chicago, Chicago
NOT_YET_RECRUITING
Washington University in St. Louis, St Louis
RECRUITING
Nebraska Cancer Specialists, Omaha
RECRUITING
MD Anderson Cancer Center, Houston
NOT_YET_RECRUITING
UCLA Medical Center, Santa Monica
COMPLETED
Hoag Hospital, Irvine
RECRUITING
Stanford Hospital and Clinics, Stanford
RECRUITING
University of Washington/Fred Hutchinson Cancer Center, Seattle
RECRUITING
Dana-Farber Cancer Institute, Boston
NOT_YET_RECRUITING
Cross Cancer Institute, Edmonton
NOT_YET_RECRUITING
"Queen Elizabeth II Health Sciences Centre, Nova Scotia Health Authority"
RECRUITING
CHUM, Montreal
RECRUITING
CIUSSS de l'Estrie - CHUS, Sherbrooke
Lead Sponsor
Collaborators (1)
AstraZeneca
INDUSTRY
Fusion Pharmaceuticals Inc.
INDUSTRY